Over the past 10 years there has been improvement in the number of recall events attributed to particle contamination of injectable drugs, yet manufacturers need to work harder to improve the quality of these products as the number of injectable recalls overall is still “significant,” a US FDA official says.
To address this problem, the agency is developing a guidance on visual testing programs to improve the quality of sterile injectable drugs, yet in the meantime an official advises industry...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?